Cardiovascular Risk Factors and Cognitive Trajectories


Peking University Sixth Hospital




Cerebral Blood Flow
Normal Cognition
Cognitive Change
Cardiovascular Risk Factors

Study type


Funder types




Details and patient eligibility


The cognitive trajectory varies among non-demented older adults. In a 12-year follow-up study, we found approximately 5% participants presented rapid cognitive decline. Cardiovascular diseases increased the risk of cognitive decline. However, the influence of cardiovascular risk factors on cognitive decline remained inconsistent. Besides, the potential mechanism of the cardiovascular risk factors and cognitive function has not been fully investigated. Therefore, the proposed program will include two sub-studies. The first sub-study will use the longitudinal data from the Chinese Longitudinal Healthy Longevity Survey to evaluate the influence of cardiovascular risk factors on the trajectories of cognitive function. The second sub-study will recruit cognitive intact older adults with different levels of cardiovascular risk factors. The association among cardiovascular risk factors, cerebral blood flow, brain functional connectivity and cognitive function will be investigated with structural equation modeling. The findings of the proposed program will provide novel insight on preventing cognitive decline from the angle of maintaining healthy vascular function, and will provide evidence in elucidating the potential neurovascular mechanism between cardiovascular risk factors and cognitive function.


8,000 estimated patients




55+ years old


Accepts Healthy Volunteers

Inclusion and exclusion criteria

For the cognitive trajectory cohort (the data had been collected):

Inclusion Criteria:

  • Aged 65 or over at baseline;
  • With normal cognitive function at baseline (score ≥ 18 on the Chinese version of Mini-Mental State Examination, MMSE);
  • Had at least one domain information about cardiovascular risk factors (hypertension, diabetes, dyslipidemia, obesity, exercise, diet and smoking) at baseline;
  • Completed cognitive function assessment at least twice during 3 waves following-up after baseline;
  • Provided informed consent voluntarily.

Exclusion Criteria:

  • Aged <65;
  • had a history of dementia or MMSE score < 18 at baseline;
  • Without more than once cognitive function assessment during the follow-up;
  • Refused to participate the survey.

For the neuroimaging sample, who would be enrolled by this study:

Inclusion Criteria:

  • Aged 55-80;
  • Right-handed;
  • Primary school education or above, with normal communication ability;
  • No complaints of cognitive impairment or decline;
  • MMSE score ≥ 26;
  • Clinical dementia rating (CDR) =0;
  • Provided informed consent voluntarily.

Exclusion Criteria:

  • Severe visual or hearing impairment, difficult to complete cognitive function assessment;
  • Had contraindications to magnetic resonance examination, such as claustrophobia, cardiac pacemaker and artificial heart valve;
  • Had cardiovascular diseases (such as myocardial infarction and unstable angina pectoris), severe respiratory diseases, malignant tumors, renal failure and other serious physical diseases;
  • Had diseases that could affect cognitive function, such as hypothyroidism, syphilis, vitamin B12 deficiency and anemia;
  • Had a history of any mental disease;
  • Had a history of cerebrovascular disease, or obvious space occupying lesions in the brain revealed by magnetic resonance examination;
  • Refused to participate the survey.

Trial design

8,000 participants in 2 patient groups

cognitive trajectory cohort
Th cognitive trajectory cohort, based on CLHLS dataset, will be used to evaluate the influence of cardiovascular risk factors on the cognitive trajectories among cognitively intact older adults
neuroiming sample
The neuroiming sample, including cognitively intact older adults with MRI data, will be used to explore the potential mechanism of the cardiovascular risk factors and cognitive function.

Trial contacts and locations



Central trial contact

Xiaozhen Lv, Ph.D; Xue Han, MD

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems